Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTOPROL vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension,Off-label: heart failure (metoprolol component), edema
Hypertension
1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Bisoprolol: 10-12 hours, allowing once-daily dosing; Hydrochlorothiazide: 6-15 hours, prolonged in renal impairment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Metoprolol: primarily CYP2D6; Hydrochlorothiazide: not metabolized, excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 40-50% as unchanged drug and metabolites (hydrochlorothiazide and bisoprolol); Fecal/Biliary: <15%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Bisoprolol: 30% bound to albumin; Hydrochlorothiazide: 40-68% bound to plasma proteins (predominantly albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Bisoprolol: 3.5 L/kg, reflecting extensive tissue distribution; Hydrochlorothiazide: 0.83 L/kg, indicating distribution in extracellular fluid.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: Bisoprolol 90% (high, first-pass negligible); Hydrochlorothiazide 65-75%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated if GFR <30 m L/min/1.73 m². For GFR 30-60 m L/min/1.73 m²: no dose adjustment required, but monitor potassium and creatinine. For GFR <30 m L/min/1.73 m²: do not use.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh Class A or B: no dose adjustment; use with caution. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not approved for use in pediatric patients (safety and efficacy not established).
Not established; avoid use in children.
Start at lowest possible dose; monitor renal function and electrolytes. No specific dose adjustment required if renal function normal, but elderly more susceptible to hypotension and electrolyte imbalance.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None.
None
Exacerbation of ischemic heart disease upon abrupt withdrawal of beta-blocker.,Bronchospasm in patients with bronchospastic disease.,May mask signs of hyperthyroidism or hypoglycemia.,Electrolyte disturbances (hypokalemia, hyponatremia) due to thiazide.,May increase serum uric acid and precipitate gout.,May cause photosensitivity reaction.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure.,Bronchial asthma or significant COPD.,Anuria or hypersensitivity to sulfonamide-derived drugs (thiazides).
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
DUTOPROL should be taken 30 minutes after the same meal each day to reduce variability in absorption. Grapefruit juice inhibits CYP3A4 and can increase dutasteride levels; avoid concomitant consumption. High-fat meals may alter absorption, but consistent timing with a meal minimizes fluctuations. No other specific food interactions are known, but maintain a balanced diet and avoid excessive alcohol, which can worsen dizziness or hypotension.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Category D: First trimester exposure associated with fetal bradycardia, intrauterine growth restriction, and oligohydramnios; second and third trimester use may cause fetal hypotension, hypoglycemia, and decreased placental perfusion.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for bradycardia and hypotension.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Dose may need reduction due to increased plasma volume and clearance; individualize based on maternal blood pressure and fetal status.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
DUTOPROL is a fixed-dose combination of dutasteride (0.5 mg) and tamsulosin (0.4 mg) used for benign prostatic hyperplasia (BPH). Due to dutasteride's long half-life (~5 weeks), clinical effect on prostate volume may take 3–6 months. Tamsulosin, an alpha-1 blocker, can cause orthostatic hypotension, especially when initiated; titrate cautiously in elderly or those on antihypertensives. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) as they increase dutasteride exposure. Measure PSA before starting and periodically thereafter; dutasteride halves PSA levels after 6 months, so adjust interpretation. Do not use in women or children.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take this medication exactly as prescribed, usually once daily, 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open the capsules; swallow them whole to avoid irritation.,This drug can cause dizziness, lightheadedness, or fainting, especially when first starting or if you take blood pressure medications. Get up slowly from sitting or lying down.,Avoid grapefruit juice and grapefruit products as they may affect how the drug works.,Inform your doctor if you experience any of the following: severe dizziness, difficulty urinating, chest pain, or signs of an allergic reaction (rash, itching, swelling).,Do not donate blood while taking this medication and for at least 6 months after stopping, as the drug can be present in blood and cause harm to a pregnant woman or her baby.,If you are having cataract surgery, tell your surgeon you are taking this drug, as it may increase the risk of intraoperative floppy iris syndrome (IFIS).,This medication may cause a decrease in sexual desire, difficulty with erections, or reduced semen volume. These side effects are generally reversible after stopping treatment.,Women who are pregnant or could become pregnant should avoid handling crushed or broken capsules due to risk of harm to the unborn baby.,Regular follow-ups with your healthcare provider for PSA testing and symptom monitoring are important to assess treatment response and adjust dose if needed.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTOPROL vs ALDORIL 25, answered by our medical review team.
DUTOPROL is a Antihypertensive Combination that works by Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTOPROL and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTOPROL is: 1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTOPROL and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTOPROL is classified as Category C. Category D: First trimester exposure associated with fetal bradycardia, intrauterine growth restriction, and oligohydramnios; second and third trimester use may cause fetal hypoten. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.